Dr. Reddy’s Laboratories Ltd. (DRREDDY) Share Price Hits Fresh 52-Week Low

Dr. Reddy’s Laboratories Ltd. Share Price fell to a fresh 52-week low of Rs 1,101, closing at Rs 1,154.3, down 2.41% today. The market cap stands at Rs 1,00,707.81 crore.

Dr. Reddy’s Laboratories Ltd. Share Price has reached a fresh 52-week low, closing at Rs 1,154.3, a decline of 2.41% from the previous close of Rs 1,182.8. The stock opened at Rs 1,101 and touched a high of Rs 1,156.1 during the day. The market capitalisation of the company is Rs 1,00,707.81 crore, highlighting its significant presence in the healthcare sector. This decline marks a notable event for investors and analysts tracking the stock, as it signifies a new yearly low.

Dr. Reddy’s Laboratories Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,154.3
Previous Close	Rs 1,182.8
Today’s Change	Rs -28.5 (-2.41%)
Day Open	Rs 1,101
Fresh 52-Week Low	Rs 1,101
Day High	Rs 1,156.1
Current Volume	37,94,255
Turnover	Rs 437.97 crore
Market Capitalisation	Rs 1,00,707.81 crore

Today’s trading session saw Dr. Reddy’s Laboratories Ltd. Share Price hit a fresh 52-week low of Rs 1,101. The stock closed at Rs 1,154.3, down Rs 28.5 or 2.41% from the previous close. The day’s turnover was Rs 437.97 crore, with a volume of 37,94,255 shares traded. The stock opened at Rs 1,101, matching its new yearly low, and reached a high of Rs 1,156.1. This price action indicates a significant shift in investor sentiment, as the stock has breached its previous 52-week low.

Dr. Reddy’s Laboratories Ltd. Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,00,707.81 crore
P/E Ratio	29.98x
P/B Ratio	0.44x
ROE	-2.89%
ROCE	-0.26%

Dr. Reddy’s Laboratories Ltd. was valued at a P/E ratio of 29.98x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Dr. Reddy’s Laboratories Ltd. has a market capitalisation of Rs 1,00,707.81 crore. The company’s P/E ratio stands at 29.98, which is above the sector median of 21.32 but below the sector average of 68.1. The P/B ratio is 0.44, significantly lower than the sector median of 1.9. The company’s ROE is -2.89%, and ROCE is -0.26%, both of which are below the sector medians of 11.09% and 13.2%, respectively. These figures suggest that the company is currently underperforming in terms of profitability and return on capital compared to its sector peers.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Companies in Benchmark	198
Company P/E Ratio	29.98x
Benchmark Median P/E	21.32x
Benchmark Average P/E	68.1x
Benchmark P/E Range	0x to 3,654.25x
Companies with P/E Data	198
Company P/B Ratio	0.44x
Benchmark Median P/B	1.9x
Company ROE	-2.89%
Benchmark Median ROE	11.09%
Company ROCE	-0.26%
Benchmark Median ROCE	13.2%
Company Market Capitalisation	Rs 1,00,707.81 crore
Benchmark Median Market Cap	Rs 139.77 crore

Dr. Reddy’s Laboratories Ltd. (DRREDDY) is classified under sector: Healthcare. The numerical benchmark uses 198 same sector companies from the supplied master-data set.

Dr. Reddy’s Laboratories Ltd. (DRREDDY) has a P/E ratio of 29.98x, which is above the benchmark median of 21.32x, a difference of +40.62%. The benchmark contains 198 companies with P/E data, ranging from 0x to 3,654.25x. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Dr. Reddy’s Laboratories Ltd. (DRREDDY) has a ROE of -2.89%, which is below the benchmark median of 11.09%, a difference of -126.06%. Dr. Reddy’s Laboratories Ltd. (DRREDDY) has a ROCE of -0.26%, which is below the benchmark median of 13.2%, a difference of -101.97%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Within the healthcare sector, Dr. Reddy’s Laboratories Ltd. is part of a competitive landscape with 198 companies. The sector’s P/E median is 21.32, with a wide range from 0 to 3654.25. The company’s P/E of 29.98 is above the median but below the average, indicating a mixed valuation position. The sector’s P/B median is 1.9, with Dr. Reddy’s significantly lower at 0.44, suggesting a potentially undervalued position in terms of book value. The company’s ROE and ROCE are both negative, contrasting with the sector’s positive medians, highlighting areas for potential improvement.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,982.01	29.98	0.44	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,790.26	41.56	8.46	28.21	26.35
Beta Drugs Ltd.	BETA	2,747.52	61.86	9.79	18.65	22.17
Sai Parenteral’s Ltd.	SAIPARENT	2,475.8	170.67	3.15	13.9	12.97
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,421.25	34.54	6.99	-2.6	16.92

Dr. Reddy’s Laboratories Ltd. (DRREDDY) has a P/E ratio of 29.98x compared with the displayed peer median of 41.56x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Dr. Reddy’s Laboratories Ltd. (DRREDDY) has a market capitalisation of Rs 1,00,707.81 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Dr. Reddy’s Laboratories Ltd. faces competition from peers such as Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., and Beta Drugs Ltd. In comparison, Dr. Reddy’s P/E ratio of 29.98 is on par with Dishman Carbogen but lower than Kwality Pharmaceuticals and Beta Drugs. The company’s market cap of Rs 1,00,707.81 crore dwarfs its peers, indicating its substantial market presence. However, its negative ROE and ROCE contrast with the positive figures of its competitors, suggesting challenges in profitability and capital efficiency.

Why Investors Are Watching Dr. Reddy’s Laboratories Ltd.

• Dr. Reddy’s Laboratories Ltd. Share Price has hit a fresh 52-week low, attracting attention.
• Fundamental analysis shows mixed valuation metrics compared to sector medians.
• Negative ROE and ROCE highlight profitability challenges.
• Significant market cap indicates a strong market presence.
• Competitive sector landscape with notable peers.

About Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Laboratories Ltd. is a leading player in the healthcare sector, involved in the development, manufacture, and marketing of a wide range of pharmaceutical products. The company operates across various segments, including generic medicines, active pharmaceutical ingredients, and proprietary products. With a strong focus on research and development, Dr. Reddy’s aims to provide affordable and innovative medicines to patients worldwide. Its extensive portfolio and global presence make it a key player in the pharmaceutical industry.

Track Dr. Reddy’s Laboratories Ltd. Share Price on Univest

Use Dr. Reddy’s Laboratories Ltd. (DRREDDY) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.

Investors can track Dr. Reddy’s Laboratories Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, 52-week levels, and market insights on Univest. Stay informed with real-time data and analysis to make informed investment decisions.

Frequently Asked Questions

What is Dr. Reddy’s Laboratories Ltd. Share Price today?

Ans. Dr. Reddy’s Laboratories Ltd. Share Price today is Rs 1,154.3, marking a decline of 2.41% from the previous close. The stock reached a fresh 52-week low of Rs 1,101 during the trading session.

Why did Dr. Reddy’s Laboratories Ltd. hit a 52-week low?

Ans. Dr. Reddy’s Laboratories Ltd. hit a 52-week low due to a decline in its share price to Rs 1,101. The exact catalyst for this decline is not specified in the available data.

How does Dr. Reddy’s Laboratories Ltd. compare to its peers?

Ans. Dr. Reddy’s Laboratories Ltd. has a higher market cap than its peers but faces challenges in profitability, with negative ROE and ROCE, contrasting with the positive figures of competitors. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd..

What is the market cap of Dr. Reddy’s Laboratories Ltd.?

Ans. The market capitalisation of Dr. Reddy’s Laboratories Ltd. is Rs 1,00,707.81 crore, indicating its significant presence in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 29.98x.

What sector does Dr. Reddy’s Laboratories Ltd. operate in?

Ans. Dr. Reddy’s Laboratories Ltd. operates in the healthcare sector, focusing on pharmaceuticals and drugs, with a diverse product portfolio and global presence. The stock belongs to the Healthcare sector. 198 comparable companies were included in the benchmark.

How does Dr. Reddy’s Laboratories Ltd.’s P/E ratio compare to the sector?

Ans. Dr. Reddy’s Laboratories Ltd.’s P/E ratio of 29.98 is above the sector median of 21.32 but below the sector average of 68.1, indicating a mixed valuation position. The company trades at a P/E ratio of 29.98x.

What is the P/B ratio of Dr. Reddy’s Laboratories Ltd.?

Ans. The P/B ratio of Dr. Reddy’s Laboratories Ltd. is 0.44, significantly lower than the sector median of 1.9, suggesting a potentially undervalued position in terms of book value. The company trades at a P/E ratio of 29.98x.

What are the ROE and ROCE of Dr. Reddy’s Laboratories Ltd.?

Ans. Dr. Reddy’s Laboratories Ltd. has an ROE of -2.89% and ROCE of -0.26%, both below the sector medians, indicating challenges in profitability and capital efficiency. ROE stands at -2.89%. ROCE stands at -0.26%.

Who are the peers of Dr. Reddy’s Laboratories Ltd.?

Ans. Peers of Dr. Reddy’s Laboratories Ltd. include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., and Beta Drugs Ltd., among others, within the healthcare sector. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Beta Drugs Ltd.